Jonathan Rosenberg presents data from a randomized noncomparative cohort of the EV-103 trial of enfortumab vedotin, investigating the agent alone or together with pembrolizumab as a first-line option for cisplatin-ineligible patients with advanced urothelial carcinoma. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

The latest findings from the EV-103 study add support for the first-line use of enfortumab vedotin plus pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

A review of trial records has identified a high rate of all-grade pneumonitis in people with metastatic urothelial carcinoma receiving enfortumab vedotin.

Updated data from the phase 3 EV-301 study show that treatment with enfortumab vedotin remains associated with improved outcomes relative to standard chemotherapy in individuals who have received prior treatment for advanced urothelial carcinoma.

Jonathan Rosenberg takes us through the 2-year follow-up data from the EV-301 study comparing enfortumab vedotin with chemotherapy in previously treated patients with advanced urothelial cancer. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Enfortumab vedotin is associated with better advanced urothelial cancer outcomes than standard chemotherapy even in patients with poor prognostic factors, suggests a subgroup analysis of the EV-301 study presented at the ESMO Congress 2021.

The quality of life data from the phase 3 EV-301 study add support for the use of enfortumab vedotin in previously treated patients with advanced urothelial carcinoma.

Durability and survival results from the phase 1b EV-103 trial provide further support for the combination of enfortumab vedotin and pembrolizumab as a promising first-line option for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma.

The phase 3 EV-301 trial has demonstrated significantly better overall survival with enfortumab vedotin than single-agent chemotherapy in advanced urothelial cancer patients who have previously received platinum-based chemotherapy and checkpoint inhibitors.

Thomas Powles outlines the primary results of the phase 3 EV-301 trial comparing enfortumab vedotin with chemotherapy in patients who have received prior treatment for locally advanced or metastatic urothelial carcinoma (4:37).

Combining enfortumab vedotin with pembrolizumab could be a promising option for the first-line treatment of cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer, indicates the EV-103 trial.

Enfortumab vedotin-ejfv has a recommended dose of 1.25 mg/kg given as a 30-minute infusion on days 1, 8 and 15 of a 28-day cycle.

Investigator Daniel Petrylak summarizes the key results of the phase II EV-201 trial of the antibody–drug conjugate enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer (2:42).

ASCO expert Robert Dreicer gives his quick take on why the enfortumab vedotin data reported at the meeting hold so much promise for advanced urothelial carcinoma patients who have progressed on prior therapy (1:25).

Preliminary results from a pivotal trial of enfortumab vedotin, an antibody–drug conjugate targeting Nectin-4, show a “clinically meaningful” response in patients with unresectable locally advanced or metastatic urothelial cancer.

They also comment on the upcoming results of the CheckMate 901 trial of nivolumab plus ipilimumab versus chemotherapy and highlight EV-302 study of enfortumab vedotin plus pembrolizumab compared with chemotherapy (21:23).

medwireNews : The EMA has adopted a positive opinion for enfortumab vedotin in urothelial cancer and for pembrolizumab in the adjuvant renal cell carcinoma (RCC) setting .

Editorial board member Axel Merseburger discusses the clinical implications of key genitourinary cancer abstracts presented at the 2021 ASCO Annual Meeting, including the KEYNOTE-564 and VISION trials, as well as brain metastases data from CheckMate 920 and updates on several enfortumab vedotin studies.

They talk about their preferred treatment approach for cisplatin-ineligible patients in the metastatic setting, commenting also on the data of enfortumab vedotin and pembrolizumab as first-line treatment for this patient population. 

Arjun Balar reports on EV-201 results suggesting that cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer may benefit from treatment with enfortumab vedotin after checkpoint inhibitor therapy (4:14).